NurExone Biologic Inc. (TSXV:NRX) (FSE:J90), a biopharmaceutical company developing biologically guided exosome therapy for patients with traumatic spinal cord injuries, has announced that it has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone’s first exotherapy product, after receiving a written response from the FDA on Aug. 29.

This is sponsored content issued on behalf of NurExone Biologic Inc., please see full disclaimer here.

Join the discussion: Find out what everybody’s saying about this stock on the NurExone Biologic Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

More From The Market Herald

Datametrex AI ousts CEO amid poor stock performance

Datametrex AI (TSXV:DM) has removed Marshall Gunter as CEO and director in a bid to improve its poor financials and stock performance.

FDA approves Alpha Cognition’s new drug application for Alzheimer’s

The U.S. Food and Drug Administration has accepted Alpha Cognition’s (CSE:ACOG) New Drug Application for its ALPHA-1062 Alzheimer's treatment.

Think Research system to support healthcare training

Think Research’s (TSXV:THNK) learning management system was chosen by a global pharma company as a bolt-on white-label education platform.

Ocumetics Technology completes animal study

Ocumetics Technology (TSXV:OTC) has completed the biocompatibility study of its accommodating intraocular lens in the eyes of rabbits.